Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin dosing regimens to reduce exacerbations in non-CF bronchiectasis
ChiCTR2100052906Phase 4Recruiting
- Sponsor
- Jiashan First People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of azithromycin in bronchiectasis (3 arms), sponsored by Jiashan First People's Hospital. Primary endpoint: Protocol-defined pulmonary exacerbations at 6 months. Started Jan 2022; status: recruiting.
02
Drugs
azithromycin
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on ChiCTR2100052906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052906.